Search Results
Search for other papers by Elke Tatjana Aristizabal Prada in
Google Scholar
PubMed
Search for other papers by Gerald Spöttl in
Google Scholar
PubMed
Search for other papers by Julian Maurer in
Google Scholar
PubMed
Search for other papers by Michael Lauseker in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Heidelberg, Germany
German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Eva Jolanthe Koziolek in
Google Scholar
PubMed
Search for other papers by Jörg Schrader in
Google Scholar
PubMed
Royal Free Hospital ENETS Centre of Excellence, London, UK
Search for other papers by Ashley Grossman in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Search for other papers by Christoph Joseph Auernhammer in
Google Scholar
PubMed
Search for other papers by Svenja Nölting in
Google Scholar
PubMed
( Fig. 4A ). Associated with the sub G1 increase and G1 phase cell cycle arrest, we found a decreased baseline CDK1(cdc2) expression and reduced baseline expression of the autophagy marker LC3AII demonstrating reduced autophagy in BON1 RR1 and BON1 RR2
Search for other papers by Jian Teng in
Google Scholar
PubMed
Search for other papers by Zun-Yi Wang in
Google Scholar
PubMed
Search for other papers by David F Jarrard in
Google Scholar
PubMed
Department of Surgical Sciences, Division of Urology, School of Veterinary Medicine, University of Wisconsin, 2015 Linden Dr, Madison, Wisconsin 53706, USA
Search for other papers by Dale E Bjorling in
Google Scholar
PubMed
containing 2% fetal bovine serum (FBS) and used between passages 4 and 6. Ureteral urothelial cells immortalized with viral constructs containing human papillomavirus E6 or E7 were also maintained in F-12+ medium and cells passaged <35 times were used. HBUC
Search for other papers by W-D Han in
Google Scholar
PubMed
Search for other papers by Y-L Zhao in
Google Scholar
PubMed
Search for other papers by Y-G Meng in
Google Scholar
PubMed
Search for other papers by L Zang in
Google Scholar
PubMed
Search for other papers by Z-Q Wu in
Google Scholar
PubMed
Search for other papers by Q Li in
Google Scholar
PubMed
Search for other papers by Y-L Si in
Google Scholar
PubMed
Search for other papers by K Huang in
Google Scholar
PubMed
Search for other papers by J-M Ba in
Google Scholar
PubMed
Search for other papers by H Morinaga in
Google Scholar
PubMed
Search for other papers by M Nomura in
Google Scholar
PubMed
Search for other papers by Y-M Mu in
Google Scholar
PubMed
Biology 17 4059 –4069. Prall OW , Sarcevic B, Musgrove EA, Watts CKW & Sutherland RL 1997 Estrogen-induced activation of Cdk4 and Cdk2 during G 1 -S phase progression ia accompanied by increased cyclin D1 expression and
Research Laboratory of Pediatrics and Nephrology, Laboratory of Functional Genomics, 2nd Department of Pathology, Center for Biological Sequence Analysis, Children's Hospital, Hungarian Academy of Sciences, Budapest, Hungary
Search for other papers by Balázs Győrffy in
Google Scholar
PubMed
Search for other papers by András Lánczky in
Google Scholar
PubMed
Research Laboratory of Pediatrics and Nephrology, Laboratory of Functional Genomics, 2nd Department of Pathology, Center for Biological Sequence Analysis, Children's Hospital, Hungarian Academy of Sciences, Budapest, Hungary
Search for other papers by Zoltán Szállási in
Google Scholar
PubMed
Panici P Mancuso S 1997 Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas . International Journal of Cancer 74 390 – 395 . doi:10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q . Masciullo V Ferrandina G
Search for other papers by Yuanliang Li in
Google Scholar
PubMed
Search for other papers by Yiying Guo in
Google Scholar
PubMed
Search for other papers by Zixuan Cheng in
Google Scholar
PubMed
Search for other papers by Chao Tian in
Google Scholar
PubMed
Search for other papers by Yingying Chen in
Google Scholar
PubMed
Search for other papers by Ruao Chen in
Google Scholar
PubMed
Search for other papers by Fuhuan Yu in
Google Scholar
PubMed
Search for other papers by Yanfen Shi in
Google Scholar
PubMed
Search for other papers by Fei Su in
Google Scholar
PubMed
Search for other papers by Shuhua Zhao in
Google Scholar
PubMed
Search for other papers by Zhizheng Wang in
Google Scholar
PubMed
Search for other papers by Jie Luo in
Google Scholar
PubMed
Department of Integrative Oncology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China
Search for other papers by Huangying Tan in
Google Scholar
PubMed
= 4), followed by MET amplification ( n = 2, 11.1%). Other potentially targetable CNVs included amplification of CDK4 , EGFR , ERBB2 , and deletion of SMARCB1 (each n = 1, 5.5%) ( Fig. 6A ). The total targetable gene list and corresponding
Ipatimup – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
ICBAS – Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Porto, Portugal
FMUP – Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Search for other papers by Tiago Bordeira Gaspar in
Google Scholar
PubMed
Ipatimup – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
FMUP – Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Department of Pathology, Centro Hospitalar e Universitário de São João, Porto, Portugal
Search for other papers by José Manuel Lopes in
Google Scholar
PubMed
Ipatimup – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
FMUP – Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Search for other papers by Paula Soares in
Google Scholar
PubMed
Ipatimup – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
FMUP – Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Search for other papers by João Vinagre in
Google Scholar
PubMed
2014, Gillam et al. described two double transgenic models using two other cell cycle regulators, cyclin-dependent kinases (Cdk) 2 and 4: Men1 +/– ;Cdk2 +/– and Men1 +/– ;Cdk4 +/– . While the first GEMM resulted in insulin-expressing tumor
Search for other papers by Philipp Mayer in
Google Scholar
PubMed
Search for other papers by Andreas Harjung in
Google Scholar
PubMed
Search for other papers by Marco Breinig in
Google Scholar
PubMed
Search for other papers by Lars Fischer in
Google Scholar
PubMed
Search for other papers by Volker Ehemann in
Google Scholar
PubMed
Search for other papers by Mona Malz in
Google Scholar
PubMed
Search for other papers by Hans Scherübl in
Google Scholar
PubMed
Search for other papers by Sarah Britsch in
Google Scholar
PubMed
Search for other papers by Jens Werner in
Google Scholar
PubMed
Search for other papers by Michael A Kern in
Google Scholar
PubMed
Search for other papers by Hendrik Bläker in
Google Scholar
PubMed
Search for other papers by Peter Schirmacher in
Google Scholar
PubMed
Search for other papers by Frank Bergmann in
Google Scholar
PubMed
; 1:500; Cell Signaling), Raf1 (1:200; Santa Cruz Biotechnologies), IGF-IRβ (C-20) (1:200; Santa Cruz Biotechnologies), CDK4 (1:500; Invitrogen), and actin (1:10.000; MP Biomedicals, Munich, Germany). All western immunoblot analyses were performed
Search for other papers by Kelly Brewer in
Google Scholar
PubMed
Center for Regenerative Medicine and Skeletal Development, Department of Reconstructive Sciences, University of Connecticut School of Dental Medicine, Farmington, Connecticut, USA
Search for other papers by Jessica Costa-Guda in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, University of Connecticut School of Medicine, Farmington, Connecticut, USA
Search for other papers by Andrew Arnold in
Google Scholar
PubMed
activation of partner cyclin-dependent kinases CDK4 and CDK6 at the G1-to-S phase transition of the cell cycle ( Sherr et al. 2016 ), and considerable evidence points to important CDK-independent actions of cyclin D1 as well ( Casimiro et al. 2015
Search for other papers by Mathieu Lupien in
Google Scholar
PubMed
Dartmouth Medical School, Division of Molecular and Cellular Oncology, Department of Medicine, Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
Search for other papers by Myles Brown in
Google Scholar
PubMed
mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry . Molecular and Cellular Biology 18 4499 – 4508 . Ruthenburg AJ Allis CD Wysocka J 2007 Methylation of lysine 4 on histone H3: intricacy of writing and reading a
Search for other papers by Lena Weindl in
Google Scholar
PubMed
Search for other papers by Imke Atreya in
Google Scholar
PubMed
Institute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Search for other papers by Peter Dietrich in
Google Scholar
PubMed
Search for other papers by Sabine Neubeck in
Google Scholar
PubMed
Deutsches Zentrum Immuntherapie DZI, Erlangen, Germany
Comprehensive Cancer Center CCC-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Search for other papers by Markus F Neurath in
Google Scholar
PubMed
Deutsches Zentrum Immuntherapie DZI, Erlangen, Germany
Comprehensive Cancer Center CCC-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
roles in cell cycle control and regulates both S-phase and G2/M progression ( Do et al . 2013 , Matheson et al. 2016 ). Phosphorylation of cyclin-dependent-kinase 2 (CDK2) by WEE1 kinase suppresses DNA replication stress. Inhibition of WEE1 leads to